Prohost Biotechnology Online

The Newsletter of Biotechnology Research and Investment

   To Subscribe Click

  Subscribe now!!!.




wpe1.jpg (4549 bytes)

P R O H O S T   O n l i n e
The Newsletter of Biotechnology Insight and Investment

Eye on the News

[ Home | Contents | Search ]


Date: 26 Jul 2000
Time: 10:53:48


AVANIR PHARMACEUTICALS was granted the first ever FDA approval of an over-the counter herpes simplex infection topical product. The most commonly used treatment for herpes now is a prescription medication called Zovirax, which is expensive. It seems that the newly approved product, doconasol cream 10%, reduces the length of time patients suffer the herpetic lesions that are painful, embarrassing and disfiguring.

It seems that more than eighty percent of adults in the U.S are carriers of the virus that causes cold sores - more than 20% of them develop symptoms that are characterized by blisters in the upper or lower lips. According to Avanir, the number of episodes that require treatments ranges from 100 to 130 million outbreak annually.

We believe that the product is filling an unmet medical need for a market that is huge. It all depends on marketing which will be conducted by the drug and marketing giant Smithkline Beecham.



Prohost is an independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at

Send mail to CompanyWebmaster with questions or comments about this web site.
Copyright 2001 CompanyLongName

Send mail to with questions or comments about this web site.
Copyright 2003 Prohost Research, Inc.